Drug Development RFP Grant

AMBER Tx Neuropharm/CCT

Strategy Notes

Applicant's pharmacological expertise (ADMET/QSAR, drug-protein interactions) is relevant; however, RFP mechanisms typically require established teams/institutions, disadvantaging independent researchers. Full assessment impossible without eligibility criteria and geographic/stage requirements.

Key Materials

—

Your Notes

Status & Deadline

Status: INELIGIBLE
Deadline: 2026-09-14
Cycle: —
Amount: —
Type: grant
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-09 OPEN → INELIGIBLE · Two independent hard blockers: (1) Funder explicitly restricts eligible applicants to 'academic institutions and biotechnology firms' — independent researcher status does not qualify, and ZYCO's legal incorporation as a formal biotechnology firm is unverified and unstated in the profile; (2) Funded research must address Alzheimer's disease and related dementias — applicant's CCT model targets addiction neuropharmacology, not AD/dementia, constituting a disease-area mismatch that cannot be remedied by framing alone.